このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Pfizer マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Meenakshi Nevatia

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	1.3yrs
CEOの所有権	n/a
経営陣の平均在職期間	1yrs
取締役会の平均在任期間	7.4yrs

経営陣の近況

Recent updates

This Is The Reason Why We Think Pfizer Limited's (NSE:PFIZER) CEO Deserves A Bump Up To Their Compensation

Aug 12

Are Institutions Heavily Invested In Pfizer Limited's (NSE:PFIZER) Shares?

Mar 10

Why Dividend Hunters Love Pfizer Limited (NSE:PFIZER)

Feb 17

Are Pfizer's (NSE:PFIZER) Statutory Earnings A Good Guide To Its Underlying Profitability?

Feb 02

Need To Know: Pfizer Limited (NSE:PFIZER) Insiders Have Been Buying Shares

Jan 18

Is Pfizer Limited's (NSE:PFIZER) Stock's Recent Performance A Reflection Of Its Financial Health?

Jan 03

What Can We Learn About Pfizer's (NSE:PFIZER) CEO Compensation?

Dec 18

Here's What Pfizer Limited's (NSE:PFIZER) Shareholder Ownership Structure Looks Like

Dec 03

Did You Participate In Any Of Pfizer's (NSE:PFIZER) Fantastic 174% Return ?

Nov 18

Are Pfizer's (NSE:PFIZER) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 03

Need To Know: Pfizer Limited (NSE:PFIZER) Insiders Have Been Buying Shares

Oct 20

Pfizer Limited's (NSE:PFIZER) Stock Is Going Strong: Is the Market Following Fundamentals?

Oct 02

Why Pfizer's (NSE:PFIZER) CEO Pay Matters

Sep 17

CEO（最高経営責任者

Meenakshi Nevatia (53 yo)

1.3yrs

在職期間

Mrs. Meenakshi Nevatia serves as Non-Executive Independent Director at TeamLease Services Ltd. since July 28, 2021. Mrs. Nevatia is the Managing Director of Stryker India since October 2018.She has focuse...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Meenakshi Nevatia	MD & CEO	1.3yrs	データなし	データなし
Amit Agarwal	Executive Director of Finance	less than a year	データなし	データなし
Anil Pattanshetty	Senior Director of Business Operations	no data	データなし	データなし
Prajeet Nair	Director of Corporate Services	16.8yrs	₹5.22m	データなし
Sharad Goswami	Senior Director of Policy & Public Affairs	no data	データなし	データなし
Shilpi Singh	Director of People Experience	no data	データなし	データなし
Chaitanya Nadkarni	India Digital Client Partner Lead	less than a year	データなし	データなし

1.0yrs

平均在職期間

経験豊富な経営陣: PFIZERの経営陣は経験豊富とはみなされません ( 1年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Meenakshi Nevatia	MD & CEO	1.3yrs	データなし	データなし
Amit Agarwal	Executive Director of Finance	less than a year	データなし	データなし
Meena Ganesh	Independent Woman Director	5.3yrs	₹2.23m	データなし
Sunil Lalbhai	Non Executive Independent Director	9.4yrs	₹2.37m	0.0054% ₹ 11.4m
Pradip Shah	Non-Executive Independent Chairman of the Board	24.6yrs	₹2.49m	データなし
Uday Khanna	Non Executive Independent Director	12.2yrs	₹2.40m	データなし

7.4yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: PFIZERの取締役会は経験豊富であると考えられます ( 7.3年の平均在任期間)。

Pfizer マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023

Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023

Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors

Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead

Recent updates

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

Full year 2024 earnings released: EPS: ₹121 (vs ₹136 in FY 2023)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024

Pfizer Limited to Report Q4, 2024 Results on May 17, 2024

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance Sheet

Third quarter 2024 earnings released: EPS: ₹28.42 (vs ₹32.93 in 3Q 2023)

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Pfizer Limited to Report Q3, 2024 Results on Feb 09, 2024

Pfizer Limited's (NSE:PFIZER) Business Is Yet to Catch Up With Its Share Price

Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023

Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023

Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors

Second quarter 2024 earnings released: EPS: ₹32.56 (vs ₹67.99 in 2Q 2023)

Pfizer Limited to Report Q2, 2024 Results on Oct 28, 2023

Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead

Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023

New major risk - Revenue and earnings growth

Pfizer Limited Announces Change in Management, Effective September 1, 2023

Pfizer Limited to Report Q1, 2024 Results on Aug 11, 2023

Upcoming dividend of ₹40.00 per share at 0.9% yield

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited, Annual General Meeting, Aug 18, 2023

Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023

Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm Injections

Price target decreased by 7.9% to ₹4,595

Pfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited to Report Fiscal Year 2023 Results on May 15, 2023

Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt Responsibly

Third quarter 2023 earnings released: EPS: ₹32.93 (vs ₹31.46 in 3Q 2022)

Pfizer India Appoints Meenakshi Nevatia as CEO

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Upcoming dividend of ₹30.00 per share

Pfizer Limited Announces Interim (Special) Dividend for the Financial Year Ending March 31, 2023, Payable on or Before September 30, 2022

Pfizer Limited Approves Declaration of Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹35.00 per share

Pfizer Announces Resignation of S. Sridhar as Managing Director

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

Mylan Pharmaceuticals Private Limited completed the acquisition of off-patent branded and generic established medicines business from Pfizer Limited (BSE:500680).

Pfizer Limited to Report Q1, 2023 Results on Aug 05, 2022

A Look At The Intrinsic Value Of Pfizer Limited (NSE:PFIZER)

Now 20% undervalued after recent price drop

Price target decreased to ₹5,201

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₹134 (vs ₹109 in FY 2021)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2022, Payable on or before September 23, 2022

Price target decreased to ₹5,654

Insufficient new directors

Insufficient new directors

Pfizer (NSE:PFIZER) Could Easily Take On More Debt

Pfizer and FDA Dropped Data Bombshell on Covid Vaccine Consumers

Price target decreased to ₹5,749

Calculating The Fair Value Of Pfizer Limited (NSE:PFIZER)

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Pfizer Limited Announces Board Changes

Pfizer Limited Announces Resignation of R. A. Shah as an Independent Director

Second quarter 2022 earnings released: EPS ₹31.25 (vs ₹28.71 in 2Q 2021)

These 4 Measures Indicate That Pfizer (NSE:PFIZER) Is Using Debt Safely

This Is The Reason Why We Think Pfizer Limited's (NSE:PFIZER) CEO Deserves A Bump Up To Their Compensation

Upcoming dividend of ₹35.00 per share

Price target increased to ₹6,099

Price target increased to ₹5,945

First quarter 2022 earnings released: EPS ₹43.69 (vs ₹27.20 in 1Q 2021)

マネジメント基準チェック /14